Cellosaurus cell line 7.159.2 (CVCL

Cellosaurus 7.159.2 (CVCL_B0L4)

Cross-references
Cell line name	7.159.2
Synonyms	50-002-7.159.2 HSFM; MEDI-573
Accession	CVCL_B0L4
Resource Identification Initiative	To cite this cell line use: 7.159.2 (RRID:CVCL_B0L4)
Comments	Group: Patented cell line. Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7424. Biotechnology: The monoclonal antibody produced by this hybridoma is tested as a potential therapeutic antibody with antineoplastic activity under the name dusigitumab. Monoclonal antibody isotype: IgG2, lambda. Monoclonal antibody target: UniProtKB; P05019; Human IGF1. Monoclonal antibody target: UniProtKB; P01344; Human IGF2. Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin.
Species of origin	Mus musculus (Mouse) (NCBI Taxonomy: 10090)
Hierarchy	Parent: CVCL_4032 (P3X63Ag8.653)
Category	Hybridoma
Publications	PubMed=21245093; DOI=10.1158/0008-5472.CAN-10-2274 Jin Gao, Jon W. Chesebrough, Susan Ann Cartlidge, Sally-Ann Ricketts, Leonard S. Incognito, Margaret Veldman-Jones, David Charles Blakey, Mohammad Tabrizi, Bahija Jallal, Pamela A. Trail, Steven Coats ...Show all 13 authors... , Klaus Bosslet, Yong S. Chang; Show fewer authors Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer Res. 71:1029-1040(2011) Patent=US9796779 Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge; Binding proteins specific for insulin-like growth factors and uses thereof. Patent number US9796779, 24-Oct-2017
Biological sample resources	ABCD; ABCD_AA677
Encyclopedic resources	Wikidata; Q108819731
Entry history
Entry creation	23-Sep-2021
Last entry update	02-May-2024
Version number	6